Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087399 | 0.79 | RAB9A (0.34) | RAB9AL3MBTL1 | |
| SCHEMBL15810284 | 0.78 | DPP4 (0.42) | POLBNPSR1L3MBTL1 | |
| SCHEMBL12197946 | 0.78 | POLB (0.53) | RAB9APOLBNPSR1L3MBTL1 | |
| SCHEMBL15810285 | 0.75 | SMN1; SMN2 (0.34) | POLBNPSR1L3MBTL1 | |
| SCHEMBL15810294 | 0.73 | ECE1 (0.33) | POLBL3MBTL1 | |
| SCHEMBL12197867 | 0.68 | RAB9A (0.41) | RAB9APOLBNPSR1L3MBTL1 | |
| SCHEMBL8418308 | 0.68 | BLM (0.43) | RAB9AL3MBTL1 | |
| SCHEMBL15808531 | 0.68 | CPN1 (0.40) | RAB9A | |
| SCHEMBL17087480 | 0.67 | PAOX (0.37) | POLBL3MBTL1 | |
| SCHEMBL15810306 | 0.66 | CHRM2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9895412-B2 | Cyclic depsipeptide compounds and their uses | CYPRALIS LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | CYPRALIS LIMITED (GB) | 2017-01-12 | — | — | US | disclosed |
| WO-2014091239-A1 | NOVEL PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF PERIODONTAL DISEASE | PERIOC LTD (GB) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007664-A1 | CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES | FKBP14, FKBP1A, PIN1 | RAB9A 3026/4885POLB 3674/4885NPSR1 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.